<?xml version="1.0" encoding="UTF-8"?>
<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on August 29, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00734539</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00001538</org_study_id>
    <secondary_id>1R01HD057956-01</secondary_id>
    <secondary_id>Pro00017720</secondary_id>
    <nct_id>NCT00734539</nct_id>
  </id_info>
  <brief_title>Fluconazole Prophylaxis for the Prevention of Candidiasis in Infants Less Than 750 Grams Birthweight</brief_title>
  <official_title>Fluconazole Prophylaxis for the Prevention of Candidiasis in Infants &lt; 750 Grams Birth</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Daniel Benjamin</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Thrasher Research Fund</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Food and Drug Administration (FDA)</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>Duke University</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The most common etiology of infection-related death or neurodevelopmental impairment in
      neonates with birthweight &lt;750 g is invasive candidiasis. Over 70% of the premature neonates
      who develop invasive candidiasis will die or suffer severe, permanent neurologic impairment.
      Fluconazole has been commonly used off-label in the neonatal intensive care unit, but
      definitive recommendations for its use in the nursery have been hampered by the limited
      number of well-designed trials. In neonates weighing &lt;750 g, appropriate dosing is not
      known, definitive safety and long-term follow up trials have not been completed, and there
      have not been well-powered trials conducted to establish the efficacy of the product using
      mortality as part of the primary endpoint. Three recent proof-of-concept studies suggest
      that fluconazole will be safe and effective, and a recently completed pharmacokinetic study
      is providing data to give preliminary dosing guidance. The next logical step in drug
      development is proposed by this research: to conduct a pivotal trial to determine the safety
      and efficacy of fluconazole in premature neonates with 2-year neurodevelopmental follow-up
      assessment.

      362 neonates, with a birthweight &lt;750g, were randomized at 33 US centers, to twice weekly
      fluconazole (6 mg/kg) or placebo for the first 6 weeks of life. The primary efficacy
      endpoint will be Candida-free survival at study day 49. The research will establish
      definitive dosing, safety, and efficacy of fluconazole; it will also provide critical
      information on the effects of fluconazole on neurodevelopmental impairment and antifungal
      resistance.

      Potential Impact:

      Approximately 17,000 neonates are born &lt;750 grams each year in the United States. Over 5000
      will die or develop invasive Candida infections. Demonstrating safety and efficacy of
      fluconazole in preterm neonates will improve the survivability and long term outcomes for
      these neonates.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      362 subjects were randomized to the study at 33 US sites. Final study visits of Month 18-22
      corrected age long term follow up were completed. Study database is locked.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2008</start_date>
  <completion_date type="Actual">April 2013</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>Death or Candidiasis</measure>
    <time_frame>study day 49</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>The primary endpoint for the study is death or candidiasis.
Death prior to study day 49.
Candidiasis prior to study day 49
Definite: isolation of Candida from normally sterile body fluid (blood, CSF, urine [obtained via sterile catheterization or suprapubic tap], peritoneal fluid).
Probable:
i. &gt; 5 days of consecutive antifungal therapy
AND both:
ii. Thrombocytopenia &lt;150,000/mm3 iii. Positive Candida culture from nonsterile site (ETS, bag urine)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Neurodevelopmental Impairment</measure>
    <time_frame>18-22 months corrected gestational age</time_frame>
    <safety_issue>No</safety_issue>
    <description>Bayley-III cognition composite score of less than 70, blindness, deafness, or cerebral palsy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Candidiasis</measure>
    <time_frame>prior to hospital discharge, up to 15 ½ months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Definite or probable</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stage II or Higher Necrotizing Enterocolitis</measure>
    <time_frame>prior to hospital discharge, up to 15 ½ months</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Focal Intestinal Perforation</measure>
    <time_frame>prior to hospital discharge, up to 15 ½ months</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Chronic Lung Disease</measure>
    <time_frame>36 weeks corrected gestational age</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patent Ductus Arterious Requiring Surgical Ligation</measure>
    <time_frame>prior to hospital discharge, up to 15 ½ months</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Periventricular Leukomalacia</measure>
    <time_frame>prior to hospital discharge, up to 15 ½ months</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Retinopathy of Prematurity Requiring Laser Surgery</measure>
    <time_frame>prior to hospital discharge, up to 15 ½ months</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of Hospitalization</measure>
    <time_frame>prior to hospital discharge, up to 15 ½ months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Positive Bacterial Infection From a Sterile Site</measure>
    <time_frame>prior to hospital discharge, up to 15 ½ months</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intraventricular Hemorrhage</measure>
    <time_frame>prior to hospital discharge, up to 15 ½ months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Grade 3 or 4</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">362</enrollment>
  <condition>Candidiasis</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>fluconazole 6mg/kg IV or PO twice weekly for 6 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo IV or PO twice weekly for 6 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fluconazole</intervention_name>
    <description>6mg/kg IV/PO twice weekly for a total of up to 12-13 doses</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Diflucan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>normal saline (IV) or 3 parts Ora Plus oral suspension vehicle and 1 part simethicone suspension (PO): will be given twice weekly PO/IV for a total of up to 12-13 doses</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Informed consent from the legally authorized representative.

          -  &gt; 48 hours of age and &lt; 120 hours old at time of first drug administration

          -  &lt; 750 g birth weight

          -  Negative blood cultures for Candida

        Exclusion Criteria:

          -  History of a hypersensitivity or severe vasomotor reaction to any azole

          -  receiving antifungal therapy for suspected/proven invasive fungal infection

          -  medical condition, in the opinion of the Investigator, may create an unacceptable
             additional risk

          -  diagnosed with invasive candidiasis or congenital Candida infection.

          -  liver failure (AST and ALT &gt; 250 U/L)

          -  renal failure (creatinine &gt; 2 mg/dL)

          -  major lethal congenital or genetic anomalies

          -  triplet or higher multiple gestations
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>5 Days</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel K Benjamin, MD MPH PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke Univerisity Medical Center, Duke Clinical Research Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Arkansas for Medical Sciences</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arkansas Childrens Hospital</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Orange County</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California-San Diego</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Florida</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baptist Medical Center</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shands Jacksonville Medical Center</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Riley Hospital</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Hospital</name>
      <address>
        <city>South Bend</city>
        <state>Indiana</state>
        <zip>46601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wesley Medical Center</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67214</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kosair Children's Hospital</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tulane University School of Medicine</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wayne State University</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Minnesota, Fairview Medical Center</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Nevada School of Medicine</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>West Jersey Hospital - Voorhees</name>
      <address>
        <city>Voorhees</city>
        <state>New Jersey</state>
        <zip>08043</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brookdale University Medical Center</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <zip>11203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kings County Hospital Center</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <zip>11203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SUNY Dowstate Medical Center</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <zip>11203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pitt County Memorial Hospital</name>
      <address>
        <city>Greenville</city>
        <state>North Carolina</state>
        <zip>27834</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Akron Children's Hospital</name>
      <address>
        <city>Akron</city>
        <state>Ohio</state>
        <zip>44313</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Health Sciences Center</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pennsylvania Hospital</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Tennessee</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38130</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Parkland Memorial Hospital</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75235</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cooks Children's Medical Center</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas Medical Branch</name>
      <address>
        <city>Galveston</city>
        <state>Texas</state>
        <zip>77555</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Children's Hospital/Baylor College of Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas - Houston</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2014</verification_date>
  <lastchanged_date>July 27, 2014</lastchanged_date>
  <firstreceived_date>August 13, 2008</firstreceived_date>
  <firstreceived_results_date>June 17, 2014</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Duke University Medical Center</investigator_affiliation>
    <investigator_full_name>Daniel Benjamin</investigator_full_name>
    <investigator_title>Professor of Pediatrics</investigator_title>
  </responsible_party>
  <keyword>Candida</keyword>
  <keyword>Neonate</keyword>
  <keyword>Fluconazole</keyword>
  <keyword>Prophylaxis</keyword>
  <keyword>Colonization</keyword>
  <keyword>Resistance</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Candidiasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Fluconazole</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Fluconazole</title>
          <description>fluconazole 6mg/kg IV or PO twice weekly for 6 weeks
fluconazole: 6 mg/kg PO/IV twice weekly x 14 doses</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Placebo IV or PO twice weekly for 6 weeks
placebo: placebo: normal saline (IV) or 3 parts Ora Plus oral suspension vehicle and 1 part simethicone suspension (PO): will be given twice weekly PO/IV for 14 doses</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Main Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="189"/>
                <participants group_id="P2" count="173"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="152">Number of subjects who participated through hospital discharge or study end</participants>
                <participants group_id="P2" count="138">Number of subjects who participated through hospital discharge or study end</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="37"/>
                <participants group_id="P2" count="35"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="33"/>
                <participants group_id="P2" count="32"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Enrolled in error; ineligible</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Long Term Follow up</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="152"/>
                <participants group_id="P2" count="138"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="118">Number of participants who completed the 18-22 months follow-up</participants>
                <participants group_id="P2" count="107">Number of participants who completed the 18-22 months follow-up</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="34"/>
                <participants group_id="P2" count="31"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Infants who received at least 1 dose of study drug (Modified Intent-to-Treat population)</population>
      <group_list>
        <group group_id="B1">
          <title>Fluconazole</title>
          <description>fluconazole 6mg/kg IV or PO twice weekly for 6 weeks
fluconazole: 6 mg/kg PO/IV twice weekly x 14 doses</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Placebo IV or PO twice weekly for 6 weeks
placebo: placebo: normal saline (IV) or 3 parts Ora Plus oral suspension vehicle and 1 part simethicone suspension (PO): will be given twice weekly PO/IV for 14 doses</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="188"/>
                <measurement group_id="B2" value="173"/>
                <measurement group_id="B3" value="361"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <description>Postnatal age at randomization</description>
          <units>days</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="3" lower_limit="3" upper_limit="4"/>
                <measurement group_id="B2" value="3" lower_limit="2" upper_limit="4"/>
                <measurement group_id="B3" value="3" lower_limit="2" upper_limit="4"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="109"/>
                <measurement group_id="B2" value="98"/>
                <measurement group_id="B3" value="207"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="79"/>
                <measurement group_id="B2" value="75"/>
                <measurement group_id="B3" value="154"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Hispanic or Latino</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="21"/>
                <measurement group_id="B2" value="25"/>
                <measurement group_id="B3" value="46"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Not Hispanic or Latino</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="167"/>
                <measurement group_id="B2" value="148"/>
                <measurement group_id="B3" value="315"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Unknown or Not Reported</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <description>2 participants specified a race as &quot;other&quot; which is not pre-specified in this list of races.</description>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>American Indian or Alaska Native</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="10"/>
                <measurement group_id="B2" value="7"/>
                <measurement group_id="B3" value="17"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Asian</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="3"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="3"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Native Hawaiian or Other Pacific Islander</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Black or African American</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="102"/>
                <measurement group_id="B2" value="94"/>
                <measurement group_id="B3" value="196"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>White</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="73"/>
                <measurement group_id="B2" value="70"/>
                <measurement group_id="B3" value="143"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>More than one race</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Unknown or Not Reported</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="2"/>
                <measurement group_id="B3" value="2"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>birth weight</title>
          <units>grams</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="653" lower_limit="570" upper_limit="700"/>
                <measurement group_id="B2" value="640" lower_limit="573" upper_limit="700"/>
                <measurement group_id="B3" value="650" lower_limit="570" upper_limit="700"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gestational Age at Birth</title>
          <units>weeks</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="25" lower_limit="24" upper_limit="26"/>
                <measurement group_id="B2" value="25" lower_limit="24" upper_limit="26"/>
                <measurement group_id="B3" value="25" lower_limit="24" upper_limit="26"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Death or Candidiasis</title>
        <description>The primary endpoint for the study is death or candidiasis.
Death prior to study day 49.
Candidiasis prior to study day 49
Definite: isolation of Candida from normally sterile body fluid (blood, CSF, urine [obtained via sterile catheterization or suprapubic tap], peritoneal fluid).
Probable:
i. &gt; 5 days of consecutive antifungal therapy
AND both:
ii. Thrombocytopenia &lt;150,000/mm3 iii. Positive Candida culture from nonsterile site (ETS, bag urine)</description>
        <time_frame>study day 49</time_frame>
        <safety_issue>Yes</safety_issue>
        <population>Modified intent-to-treat; only subjects who received at least one dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Fluconazole</title>
            <description>fluconazole 6mg/kg IV or PO twice weekly for 6 weeks
fluconazole: 6 mg/kg PO/IV twice weekly x 14 doses</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo IV or PO twice weekly for 6 weeks
placebo: placebo: normal saline (IV) or 3 parts Ora Plus oral suspension vehicle and 1 part simethicone suspension (PO): will be given twice weekly PO/IV for 14 doses</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="188"/>
                  <measurement group_id="O2" value="173"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Death or Candidiasis</title>
            <description>The primary endpoint for the study is death or candidiasis.
Death prior to study day 49.
Candidiasis prior to study day 49
Definite: isolation of Candida from normally sterile body fluid (blood, CSF, urine [obtained via sterile catheterization or suprapubic tap], peritoneal fluid).
Probable:
i. &gt; 5 days of consecutive antifungal therapy
AND both:
ii. Thrombocytopenia &lt;150,000/mm3 iii. Positive Candida culture from nonsterile site (ETS, bag urine)</description>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="31"/>
                  <measurement group_id="O2" value="37"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Neurodevelopmental Impairment</title>
        <description>Bayley-III cognition composite score of less than 70, blindness, deafness, or cerebral palsy</description>
        <time_frame>18-22 months corrected gestational age</time_frame>
        <safety_issue>No</safety_issue>
        <population>Attended the follow-up visit and had complete data on composite endpoint</population>
        <group_list>
          <group group_id="O1">
            <title>Fluconazole</title>
            <description>fluconazole 6mg/kg IV or PO twice weekly for 6 weeks
fluconazole: 6 mg/kg PO/IV twice weekly x 14 doses</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo IV or PO twice weekly for 6 weeks
placebo: placebo: normal saline (IV) or 3 parts Ora Plus oral suspension vehicle and 1 part simethicone suspension (PO): will be given twice weekly PO/IV for 14 doses</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="87"/>
                  <measurement group_id="O2" value="84"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Neurodevelopmental Impairment</title>
            <description>Bayley-III cognition composite score of less than 70, blindness, deafness, or cerebral palsy</description>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="27"/>
                  <measurement group_id="O2" value="23"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Candidiasis</title>
        <description>Definite or probable</description>
        <time_frame>prior to hospital discharge, up to 15 ½ months</time_frame>
        <safety_issue>Yes</safety_issue>
        <population>Modified intent-to-treat; only subjects who received at least one dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Fluconazole</title>
            <description>fluconazole 6mg/kg IV or PO twice weekly for 6 weeks
fluconazole: 6 mg/kg PO/IV twice weekly x 14 doses</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo IV or PO twice weekly for 6 weeks
placebo: placebo: normal saline (IV) or 3 parts Ora Plus oral suspension vehicle and 1 part simethicone suspension (PO): will be given twice weekly PO/IV for 14 doses</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="188"/>
                  <measurement group_id="O2" value="173"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Candidiasis</title>
            <description>Definite or probable</description>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="8"/>
                  <measurement group_id="O2" value="19"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Stage II or Higher Necrotizing Enterocolitis</title>
        <time_frame>prior to hospital discharge, up to 15 ½ months</time_frame>
        <safety_issue>Yes</safety_issue>
        <population>Modified intent-to-treat; only subjects who received at least one dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Fluconazole</title>
            <description>fluconazole 6mg/kg IV or PO twice weekly for 6 weeks
fluconazole: 6 mg/kg PO/IV twice weekly x 14 doses</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo IV or PO twice weekly for 6 weeks
placebo: placebo: normal saline (IV) or 3 parts Ora Plus oral suspension vehicle and 1 part simethicone suspension (PO): will be given twice weekly PO/IV for 14 doses</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="188"/>
                  <measurement group_id="O2" value="173"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Stage II or Higher Necrotizing Enterocolitis</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="25"/>
                  <measurement group_id="O2" value="23"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Focal Intestinal Perforation</title>
        <time_frame>prior to hospital discharge, up to 15 ½ months</time_frame>
        <safety_issue>Yes</safety_issue>
        <population>Modified intent-to-treat; only subjects who received at least one dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Fluconazole</title>
            <description>fluconazole 6mg/kg IV or PO twice weekly for 6 weeks
fluconazole: 6 mg/kg PO/IV twice weekly x 14 doses</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo IV or PO twice weekly for 6 weeks
placebo: placebo: normal saline (IV) or 3 parts Ora Plus oral suspension vehicle and 1 part simethicone suspension (PO): will be given twice weekly PO/IV for 14 doses</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="188"/>
                  <measurement group_id="O2" value="173"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Focal Intestinal Perforation</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="16"/>
                  <measurement group_id="O2" value="9"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Chronic Lung Disease</title>
        <time_frame>36 weeks corrected gestational age</time_frame>
        <safety_issue>No</safety_issue>
        <population>Modified intent-to-treat; only subjects who received at least one dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Fluconazole</title>
            <description>fluconazole 6mg/kg IV or PO twice weekly for 6 weeks
fluconazole: 6 mg/kg PO/IV twice weekly x 14 doses</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo IV or PO twice weekly for 6 weeks
placebo: placebo: normal saline (IV) or 3 parts Ora Plus oral suspension vehicle and 1 part simethicone suspension (PO): will be given twice weekly PO/IV for 14 doses</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="188"/>
                  <measurement group_id="O2" value="173"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Chronic Lung Disease</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="114"/>
                  <measurement group_id="O2" value="93"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patent Ductus Arterious Requiring Surgical Ligation</title>
        <time_frame>prior to hospital discharge, up to 15 ½ months</time_frame>
        <safety_issue>Yes</safety_issue>
        <population>Modified intent-to-treat; only subjects who received at least one dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Fluconazole</title>
            <description>fluconazole 6mg/kg IV or PO twice weekly for 6 weeks
fluconazole: 6 mg/kg PO/IV twice weekly x 14 doses</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo IV or PO twice weekly for 6 weeks
placebo: placebo: normal saline (IV) or 3 parts Ora Plus oral suspension vehicle and 1 part simethicone suspension (PO): will be given twice weekly PO/IV for 14 doses</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="188"/>
                  <measurement group_id="O2" value="173"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Patent Ductus Arterious Requiring Surgical Ligation</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="46"/>
                  <measurement group_id="O2" value="43"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Periventricular Leukomalacia</title>
        <time_frame>prior to hospital discharge, up to 15 ½ months</time_frame>
        <safety_issue>Yes</safety_issue>
        <population>Modified intent-to-treat; only subjects who received at least one dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Fluconazole</title>
            <description>fluconazole 6mg/kg IV or PO twice weekly for 6 weeks
fluconazole: 6 mg/kg PO/IV twice weekly x 14 doses</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo IV or PO twice weekly for 6 weeks
placebo: placebo: normal saline (IV) or 3 parts Ora Plus oral suspension vehicle and 1 part simethicone suspension (PO): will be given twice weekly PO/IV for 14 doses</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="188"/>
                  <measurement group_id="O2" value="173"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Periventricular Leukomalacia</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="10"/>
                  <measurement group_id="O2" value="6"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Retinopathy of Prematurity Requiring Laser Surgery</title>
        <time_frame>prior to hospital discharge, up to 15 ½ months</time_frame>
        <safety_issue>Yes</safety_issue>
        <population>Modified intent-to-treat; only subjects who received at least one dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Fluconazole</title>
            <description>fluconazole 6mg/kg IV or PO twice weekly for 6 weeks
fluconazole: 6 mg/kg PO/IV twice weekly x 14 doses</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo IV or PO twice weekly for 6 weeks
placebo: placebo: normal saline (IV) or 3 parts Ora Plus oral suspension vehicle and 1 part simethicone suspension (PO): will be given twice weekly PO/IV for 14 doses</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="188"/>
                  <measurement group_id="O2" value="173"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Retinopathy of Prematurity Requiring Laser Surgery</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="29"/>
                  <measurement group_id="O2" value="25"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Length of Hospitalization</title>
        <time_frame>prior to hospital discharge, up to 15 ½ months</time_frame>
        <safety_issue>No</safety_issue>
        <population>Modified intent-to-treat; only subjects who received at least one dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Fluconazole</title>
            <description>fluconazole 6mg/kg IV or PO twice weekly for 6 weeks
fluconazole: 6 mg/kg PO/IV twice weekly x 14 doses</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo IV or PO twice weekly for 6 weeks
placebo: placebo: normal saline (IV) or 3 parts Ora Plus oral suspension vehicle and 1 part simethicone suspension (PO): will be given twice weekly PO/IV for 14 doses</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="188"/>
                  <measurement group_id="O2" value="173"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Length of Hospitalization</title>
            <units>days</units>
            <param>Median</param>
            <dispersion>Inter-Quartile Range</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="113" lower_limit="90" upper_limit="148"/>
                  <measurement group_id="O2" value="107" lower_limit="88" upper_limit="128"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Positive Bacterial Infection From a Sterile Site</title>
        <time_frame>prior to hospital discharge, up to 15 ½ months</time_frame>
        <safety_issue>Yes</safety_issue>
        <population>Modified intent-to-treat; only subjects who received at least one dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Fluconazole</title>
            <description>fluconazole 6mg/kg IV or PO twice weekly for 6 weeks
fluconazole: 6mg/kg IV/PO twice weekly for a total of up to 12-13 doses</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo IV or PO twice weekly for 6 weeks
placebo: normal saline (IV) or 3 parts Ora Plus oral suspension vehicle and 1 part simethicone suspension (PO): will be given twice weekly for a total of up to 12-13 doses</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="188"/>
                  <measurement group_id="O2" value="173"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Positive Bacterial Infection From a Sterile Site</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="109"/>
                  <measurement group_id="O2" value="100"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Intraventricular Hemorrhage</title>
        <description>Grade 3 or 4</description>
        <time_frame>prior to hospital discharge, up to 15 ½ months</time_frame>
        <safety_issue>Yes</safety_issue>
        <population>Modified intent-to-treat; only subjects who received at least one dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Fluconazole</title>
            <description>fluconazole 6mg/kg IV or PO twice weekly for 6 weeks
fluconazole: 6mg/kg IV/PO twice weekly for a total of up to 12-13 doses</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo IV or PO twice weekly for 6 weeks
placebo: normal saline (IV) or 3 parts Ora Plus oral suspension vehicle and 1 part simethicone suspension (PO): will be given twice weekly PO/IV for a total of up to 12-13 doses</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="188"/>
                  <measurement group_id="O2" value="173"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Intraventricular Hemorrhage</title>
            <description>Grade 3 or 4</description>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="33"/>
                  <measurement group_id="O2" value="31"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From time of first dose of study drug until 30 days following the last dose, up to approximately 10 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Fluconazole</title>
          <description>fluconazole 6mg/kg IV or PO twice weekly for 6 weeks
fluconazole: 6 mg/kg PO/IV twice weekly x 14 doses</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo IV or PO twice weekly for 6 weeks
placebo: placebo: normal saline (IV) or 3 parts Ora Plus oral suspension vehicle and 1 part simethicone suspension (PO): will be given twice weekly PO/IV for 14 doses</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="83" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="68" subjects_at_risk="173"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="173"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Bradycardia Neonatal</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="173"/>
              </event>
              <event>
                <sub_title>Neonatal Cardiac Failure</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="173"/>
              </event>
              <event>
                <sub_title>Cardio-Respiratory Arrest</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="173"/>
              </event>
              <event>
                <sub_title>Cardio-Respiratory Arrest Neonatal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="173"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Patent Ductus Arteriosus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="173"/>
              </event>
              <event>
                <sub_title>Ileal Atresia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="173"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Adrenal Insufficiency</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="173"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Retinopathy of Prematurity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="173"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Necrotising Enterocolitis Neonatal</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="173"/>
              </event>
              <event>
                <sub_title>Intestinal Perforation</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="173"/>
              </event>
              <event>
                <sub_title>Meconium Ileus</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="173"/>
              </event>
              <event>
                <sub_title>Colonic Stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="173"/>
              </event>
              <event>
                <sub_title>Ileal Perforation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="173"/>
              </event>
              <event>
                <sub_title>Intestinal Ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="173"/>
              </event>
              <event>
                <sub_title>Intestinal Obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="173"/>
              </event>
              <event>
                <sub_title>Peritoneal Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="173"/>
              </event>
              <event>
                <sub_title>Pneumoperitoneum</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="173"/>
              </event>
              <event>
                <sub_title>Rectal Prolapse</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="173"/>
              </event>
              <event>
                <sub_title>Small Intestinal Perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="173"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Neonatal Multi-Organ Failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="173"/>
              </event>
              <event>
                <sub_title>Infusion Site Extravasation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="173"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Sepsis Neonatal</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="173"/>
              </event>
              <event>
                <sub_title>Staphylococcal Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="173"/>
              </event>
              <event>
                <sub_title>Osteomyelitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="173"/>
              </event>
              <event>
                <sub_title>Arthritis Bacterial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="173"/>
              </event>
              <event>
                <sub_title>Candida Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="173"/>
              </event>
              <event>
                <sub_title>Candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="173"/>
              </event>
              <event>
                <sub_title>Group B Streptococcus Neonatal Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="173"/>
              </event>
              <event>
                <sub_title>Meningitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="173"/>
              </event>
              <event>
                <sub_title>Pneumonia Klebsiella</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="173"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Endotracheal Intubation Complication</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="173"/>
              </event>
              <event>
                <sub_title>Gastrointestinal Stoma Complication</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="173"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Bilirubin Conjugated Increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="173"/>
              </event>
              <event>
                <sub_title>Oxygen Saturation Decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="173"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Soft Tissue Necrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="173"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Intraventricular Haemorrhage Neonatal</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="173"/>
              </event>
              <event>
                <sub_title>Hydrocephalus</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="173"/>
              </event>
              <event>
                <sub_title>Convulsion Neonatal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="173"/>
              </event>
              <event>
                <sub_title>Cerebral Ventricle Dilatation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="173"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal Failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="173"/>
              </event>
              <event>
                <sub_title>Renal Failure Neonatal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="173"/>
              </event>
              <event>
                <sub_title>Renal Failure Acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="173"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Neonatal Respiratory Failure</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="173"/>
              </event>
              <event>
                <sub_title>Neonatal Respiratory Arrest</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="173"/>
              </event>
              <event>
                <sub_title>Neonatal Respiratory Distress Syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="173"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="173"/>
              </event>
              <event>
                <sub_title>Bronchopleural Fistula</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="173"/>
              </event>
              <event>
                <sub_title>Pleural Effusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="173"/>
              </event>
              <event>
                <sub_title>Pulmonary Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="173"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin Necrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="173"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Neonatal Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="173"/>
              </event>
              <event>
                <sub_title>Deep Vein Thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="173"/>
              </event>
              <event>
                <sub_title>Vena Cava Thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="173"/>
              </event>
              <event>
                <sub_title>Venous Thrombosis Limb</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="173"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="173"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperbilirubinaemia Neonatal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="173"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Gamma-Glutamyltransferase Increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="188"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="173"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Daniel K. Benjamin Jr</name_or_title>
      <organization>Duke Univiersity Medical Center</organization>
      <phone>919-668-7081</phone>
      <email>danny.benjamin@dm.duke.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
